• Confo Therapeutics

  Participated · Series B · Jul 2024

  Confo Therapeutics employs a proprietary discovery platform using conformation-specific ConfoBodies® to stabilize GPCRs in functionally relevant states and discover small molecules and agonistic antibodies. The company is building a pipeline focused on metabolic and endocrine diseases, including programs directed at obesity and severe rare endocrine disorders. Confo plans to advance two wholly owned programs through Phase 1 and bring two additional programs to IND approval, with explicit efforts on molecules targeting GPR75 for obesity. The company emphasizes both small-molecule GPCR modulators and therapeutic antibodies, notably agonistic antibodies. Confo is headquartered in Ghent, Belgium. Its current financial position includes the recently closed EUR 60M Series B financing to accelerate its development pipeline. Confo Therapeutics develops ConfoBodyTM single-domain camelid antibodies that selectively stabilize G-protein coupled receptors (GPCRs) to enable drug discovery. The company is building a portfolio of first-in-class programs based on its Confo® technology. It operates both internal discovery programs and revenue-generating partnerships with pharma on non-competing GPCR targets. Confo Therapeutics has active collaborations with Lundbeck and Roche to apply its platform. The firm plans to use new capital to advance its pipeline of GPCR-modulating compounds toward clinical candidates. The company was co-founded in 2015 as a VUB–VIB spin-off and is based in Ghent, Belgium. Confo Therapeutics is an emerging drug-discovery company based in Ghent, Belgium, that uses its proprietary Confo® technology to discover new GPCR agonist compounds for the treatment of fibrosis. The company operates a Drug Discovery Center in Gent and a Target Discovery Center in Brussels. It is expanding the applicability of its Confo® platform, supported by recent grant awards. Financially, Confo Therapeutics has been awarded non-dilutive funding totaling roughly €2.6 million to support its discovery programs. Part of the funding will be allocated over a two-year VLAIO grant primarily to the Gent Drug Discovery Center, while the Innoviris award will support work at the Brussels Target Discovery Center. The company’s near-term plans, as described in the awards, focus on fibrosis compound discovery and broadening the Confo® technology’s use.

• EclecticIQ

  Participated · Equity · Mar 2024

  EclecticIQ builds an analyst-centric, open and extendable cybersecurity platform that combines threat intelligence automation and collaboration with forensic endpoint visibility and threat detection and response. Founded in 2014 by Joep Gommers and Raymon van der Velde, the company helps governments, large enterprises, and service providers manage threat intelligence and create situational awareness. It extended into hunting and response after acquiring Polylogyx's endpoint technology in 2020. The company operates worldwide with teams and offices in Europe, the UK, North America and India and works through value-added partners. EclecticIQ plans to use recent financing to accelerate R&D, further develop its platform, and expand into new countries and sectors through sales and marketing investment. The articles position the firm as a scale-up addressing a rising global cyber threat landscape. EclecticIQ develops threat intelligence, hunting and response technology that helps large enterprises, service providers and governments manage threat intelligence and create situational awareness. The company extended its capabilities into hunting and response with the 2020 acquisition of Polylogyx’s endpoint technology. EclecticIQ intends to use new funding to expand its product portfolio with additional use cases and to promote an intelligence-led cybersecurity approach. Management plans to increase its global presence by extending commercial teams in Europe and the United States and establishing operations in the Middle East, Africa and Asia Pacific. The company also aims to strengthen its global partner ecosystem. Founded in 2014, EclecticIQ operates globally with offices across Europe, North America and via certified value-add partners. EclecticIQ offers an analyst-centric suite of cyber threat intelligence products, including the EclecticIQ Platform (based on STIX/TAXII) and the EclecticIQ Fusion Center for acquiring thematic intelligence bundles. The company targets security professionals in threat intelligence, threat hunting, SOC, and incident response roles. It employs a team of about 60 across offices in Amsterdam, London, and Herndon (Virginia, USA). EclecticIQ intends to use its latest funding to accelerate workforce expansion and to broaden its portfolio of technologies and Fusion Center capabilities. Financially, the company has raised more than €20m to date following its latest round. Founded in 2014 by Joep Gommers and Raymon van der Velde, EclecticIQ continues to expand its product and service offerings for enterprise security operations. EclecticIQ provides a Threat Intelligence Platform (TIP) that enables operationalization of security information exchange, empowers collaborative analyst workflow and integrates cyber threat intelligence for detection, prevention and response. Led by CEO and founder Joep Gommers, the company mainly serves financial institutions and government agencies. It is based in Amsterdam and also maintains offices in London and Chișinău, Moldova. EclecticIQ secured a €5.5m Series A and has raised €6.5m in total (approx. $7.3m). The company said it will use the new funds to expand across sectors and geographies. No other operating metrics were disclosed in the article.

• Sensolus

  Participated · Equity · Oct 2020

  Sensolus builds stick-on wireless trackers and a cloud SaaS platform to track non-powered assets across supply chains and industrial manufacturing. The sticker sensors last seven years without charging and can communicate in real time without additional infrastructure. The SaaS platform combines sensor data with existing process data to generate supply chain metrics and help optimise logistics. The product is used in 15 countries by customers including Airbus, Volvo, AB InBev, SUEZ and T.C.R. Founded in 2013 and based in Ghent, Sensolus plans to expand throughout Europe and the US and to broaden the types of omnipresent assets its solution can connect. The company recently raised funding to develop and expand its logistics system and product. Ghent-based Sensolus develops an industrial IoT tracking and monitoring system called STICKNTRACK. Its customers include Airbus, which uses the system together with the Sigfox network to track aircraft components between different sites. The company is currently active in Europe and plans to use the new funding to grow internationally. Sensolus said it will invest strongly in its sales and business teams as part of that expansion. It raised €2.75 million from Capricorn ICT Arkiv and Quest for Growth to fuel international growth. Capricorn’s Marc Lambrechts will be joining Sensolus’ board.

• Miracor Medical

  Participated · Series E · Sep 2020

  Miracor Medical Systems GmbH develops and commercializes the Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System, an adjunct therapy designed to reduce myocardial injury and revitalize ischemic myocardium during and after primary PCI procedures. The CE-marked system comprises a reusable console and a single-use catheter and has shown encouraging results on MACE, restenosis rates, and event-free survival in early clinical work. A 10-patient feasibility study in Amsterdam demonstrated successful use of the technology, prompting the company to launch the pivotal RAMSES trial in STEMI patients. Miracor envisions PICSO becoming the standard of care for heart attack treatment, targeting the 30% of acute coronary syndrome cases that suffer suboptimal reperfusion—an addressable market of more than 350,000 patients annually in the U.S. and Europe. Beyond ACS, the technology is being explored for heart failure and cardiac surgery applications. The firm recently secured $3.5 million in non-dilutive funding to support its pivotal study, bolstering its financial position for the next phase of clinical validation.

• HalioDx

  Participated · Series B · Jan 2018

  HalioDx operates Immunoscore, a diagnostic platform that combines immunohistochemistry and advanced digital pathology to analyze the tumor microenvironment and help oncologists optimize patient management. In colon cancer the company has accumulated strong clinical evidence for predicting individual risk of recurrence and is progressing toward reimbursement decisions in several countries. HalioDx has developed an immune biomarker partnering program with biopharma to assess the predictive value of Immunoscore and other proprietary assays, notably Immunosign and Halioseek, across various therapeutic modalities and indications, including companion diagnostics approaches for specific immunotherapies. The company intends to use the proceeds of the recent financing to accelerate development of Immunoscore for colon cancer and selected additional cancer types and to establish commercial activities in the US. HalioDx has a team of more than 130 employees, operates a CLIA laboratory, and maintains compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products.

No current team members are available.